Results 61 to 70 of about 30,754 (261)

Novel approaches in the pharmacotherapy of Heart Failure with preserved Ejection Fraction

, 2022
This work discusses a short introduction of HFpEF with epidemiology, prevalence, classification, aetiology, pathophysiology, and the important molecular pathway contributing to it.
Liu, Chin Ting
core  

Glucagon-Like Peptide-1 Agonists and the Incidence of Atrial Fibrillation in Obese Patients With Heart Failure With Preserved Ejection Fraction and No Diabetes. [PDF]

J Arrhythm
Among obese, non‐diabetic patients with HFpEF, GLP‐1 RA therapy was not significantly associated with incident atrial fibrillation but was associated with lower all‐cause mortality. Prospective studies are needed to clarify the potential role of GLP‐1 RAs in AF prevention. ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) reduce
Rassam F, Lopez EK, Sass S, Srikulmontri T, Isaacs E, Malin J, Wattanachayakul P, Afolabi-Brown O.   +7 more
europepmc   +2 more sources

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Ultrasound-derived congestion phenotypes and their association with cardiac structure and function in HFpEF [PDF]

Exploration of Medicine
Aim: To evaluate ultrasound-derived congestion phenotypes in acute decompensated heart failure with preserved ejection fraction (HFpEF) and their association with cardiac remodeling and in-hospital outcomes.
Elizaveta A. Rogozhkina, Anna A. Ivanova, Olga N. Dzhioeva, Anton R. Kiselev, Oksana M. Drapkina   +4 more
doaj   +1 more source

Lean ZSF1 rats in basic research on heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1474-1478, April 2025.
Abstract Aims ZSF1 obese rats harbouring two mutant leptin receptor alleles (Leprcp and Leprfa) develop metabolic syndrome and heart failure with preserved ejection fraction (HFpEF), making them a widely used animal model in cardiometabolic research.
Petra Büttner, Antje Augstein, Mahmoud Abdellatif, André Lourenço, Adelino Leite‐Moreira, Inês Falcão‐Pires, Sarah Werner, Holger Thiele, Simon Sedej, Antje Schauer, Volker Adams   +10 more
wiley   +1 more source

Diastolische Dysfunktion und HFpEF bei CKD: Ein Update [Diastolic dysfunction and HFpEF in CKD: An update]

, 2023
Cardiac and renal (dys)functions are closely linked. Common risk factors lead to simultaneous or sequential loss of function of both organs, and derailed compensatory mechanisms promote progression to heart and renal failure.
Wilck, N., Szijártó, I.A.
core   +1 more source

Associations of Depression, Antidepressants with Atrial Fibrillation Risk in HFpEF Patients

Reviews in Cardiovascular Medicine
Background: Studies dedicated to exploring the incidence of atrial fibrillation (AF) in patients with concurrent depression and heart failure with preserved ejection fraction (HFpEF) are scarce.
Yonghui Fu, Shenghui Feng, Zhenbang Gu, Xiao Liu, Wengen Zhu, Bo Wei, Linjuan Guo   +6 more
doaj   +1 more source

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source

Pathogenesis and Therapeutic Advances in Heart Failure with Preserved Ejection Fraction

Reviews in Cardiovascular Medicine
Heart failure with preserved ejection fraction (HFpEF) has progressively emerged as the predominant form of heart failure. Thus, studies on the underlying mechanisms of HFpEF have shifted from pathophysiological to molecular factors.
Xin Fan, Jie Ma, Xu Zhao, Jing Yu
doaj   +1 more source